Advances in Good Manufacturing Practice guidelines for sterile pharmaceutical products
DOI:
https://doi.org/10.14450/2318-9312.v35.e3.a2023.pp364-374Keywords:
drug industry, good manufacturing practices, drug contamination, risk management, sanitary inspection, pharmaceutical quality system.Abstract
The microbiological contamination of medicines represents a significant risk to the patient. The control of microbial contamination must cover all stages of product development. Recently, the Annex 1 of the European Medicines Agency (EMA), which deals with Good Manufacturing Practices for sterile medicinal products, has been revised in collaboration with the Pharmaceutical Inspection Cooperation Scheme (PIC/S) and the World Health Organization (WHO). This study aimed to discuss the main aspects of the revision of Annex 1 of the EMA, comparing it to national normative acts,
focusing on aseptic processing and control of clean areas to manufacture sterile drugs. To this end, a comprehensive search was carried out in electronic health regulatory sites and scientific databases to retrieve material on the subject. With the publication of Annex 1 of the EMA, there is a great tendency to update Brazilian norms related to good practices in the manufacture of medicines. When comparing the current normative acts, such as RDC 658/2022 and IN 35/2019, given the publication of Annex I of the EMA, a high normative impact is observed, either due to the greater detailing of essential items or the introduction of new requirements. Following the assumptions of Good Manufacturing Practice, establishments are expected to improve their processes increasingly, in addition to regulations, aiming to mitigate the risks inherent in any manufacturing process, providing safe and effective medicines to the entire population.
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish in this journal agree to the following terms:
- Authors retain the copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Licença Creative Commons Attribution which allows the sharing of work with acknowledgment of authorship and initial publication in this journal.
- Authors are authorized to take additional contracts separately, for non-exclusive distribution of the version of the work published in this journal (e.g. publish in institutional repository or as a book chapter), with acknowledgment of authorship and initial publication in this journal.
- Authors are allowed and encouraged to publish and distribute their work online (e.g. in institutional repositories or on their personal page) at any point before or during the editorial process, as this can generate productive changes as well as increase the impact and Citation of published work (See O Efeito do Acesso Livre ).
